%PDF-1.4
%
84 0 obj
<>
endobj
81 0 obj
<>
endobj
142 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-08T11:31:10Z
2024-03-28T18:04:25-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T18:04:25-07:00
application/pdf
Heather
200233.february
uuid:19290324-1dd2-11b2-0a00-550827bd3700
uuid:19290326-1dd2-11b2-0a00-5b0000000000
endstream
endobj
70 0 obj
<>
endobj
71 0 obj
<>
endobj
85 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 56 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 58 0 R/Type/Page>>
endobj
31 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 60 0 R/Type/Page>>
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 62 0 R/Type/Page>>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 64 0 R/Type/Page>>
endobj
176 0 obj
[180 0 R]
endobj
177 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.228 Tw 10 0 0 10 54 713.1632 Tm
(center trial was performed to determine whether weekly)Tj
0.03239 Tw 0 -1.2 TD
[(administration of LJP)-245.6 (394 reduced the time to renal flare in)]TJ
0.0719 Tw T*
[(patients with a history of lupus nephritis. )17.7 (The results of an)]TJ
0.009 Tc 0.36591 Tw T*
(interim analysis revealed that the drug is capable of)Tj
-0.00011 Tc 0.1021 Tw T*
[(reducing dsDNA)-297.3 (antibody titers, but renal flare rates were)]TJ
0.18401 Tw T*
[(initially believed to be no dif)17.7 (ferent between placebo and)]TJ
0.22659 Tw T*
[(treatment groups. )54.8 (As a result, the study was terminated.)]TJ
0.3165 Tw T*
[(Clinical trials with LJP)-529.8 (394 may elucidate the role of)]TJ
0.02499 Tw T*
[(dsDNA)-220.2 (antibodies in SLE.)]TJ
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
0.2635 Tw 8 0 0 8 54 583.1632 Tm
[(The authors acknowledge the work of the study coordinators: )54.8 (Angela)]TJ
0.0137 Tw 0 -1.25 TD
[(Flesch\216, RN, CCRC; Carol )17.7 (T)35 (uggle, RN, PhN, CCRC; Kim Barnish; Judith)]TJ
0.037 Tw T*
[(Himmel, RN; Nancy Helmke, RN; Michele )17.8 (Thomas; Suzin Hagar; Denise)]TJ
0.0029 Tc 0.37199 Tw T*
[(Mathes, RN; Karen Orlof)17.8 (f, CCRC; Ruth Stewart, RN; and Martha)]TJ
-0.00011 Tc -0.0296 Tw T*
[(W)39.8 (illiams. )17.7 (The authors also acknowledge La Jolla Pharmaceutical Company)]TJ
-0.036 Tw T*
[(and )54.8 (Abbott Laboratories for validating dsDNA)-159.2 (antibody titers, for statistical)]TJ
-0.007 Tw T*
(analyses, and for evaluating and summarizing the clinical data generated\
in)Tj
0.02499 Tw T*
[(this study)64.8 (.)]TJ
/T1_1 1 Tf
0 Tw 10 0 0 10 54 489.1632 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 479.1632 Tm
[(1.)-875.1 (W)39.8 (infield JB, Faiferman I, Kof)17.7 (fler D. )54.8 (A)74 (vidity of anti-DNA)]TJ
1.675 -1.25 Td
(antibodies in serum and IgG glomerular eluates from patients with)Tj
T*
(systemic lupus erythematosus; association of high avidity antinative)Tj
T*
[(DNA)-220.2 (antibody with glomerulonephritis. J Clin Invest 1977;59:90-6.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (ter Bor)17.7 (g EJ, Host G, Hummel EJ, Limbur)17.7 (g PC, Kallenber)17.7 (g CGM.)]TJ
1.675 -1.25 Td
[(Measurement of increases in anti-double stranded DNA)-220.2 (antibody)]TJ
T*
(levels as a predictor of disease exacerbation in systemic lupus)Tj
T*
[(erythematosus. )54.8 (Arthritis Rheum 1990;33:634-43.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Jones DS, Barstad P)91.7 (A, Field MJ, et al. Immunospecific reduction of)]TJ
1.675 -1.25 Td
(antioligonucleotide antibody-forming cells with a tetrakis-)Tj
T*
[(oligonucleotide conjugate \(LJP)-238.2 (394\), a therapeutic candidate for the)]TJ
T*
(treatment of lupus nephritis. J Med Chem 1995;38:2138-44.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Coutts SM, Plunkett ML, Iverson GM, Barstad P)91.7 (A, Berner CM.)]TJ
1.675 -1.25 Td
(Pharmacologic intervention in antibody mediated disease. Lupus)Tj
0 Tc 0 Tw T*
(1996;5:158-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (W)79.9 (eisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction)]TJ
1.675 -1.25 Td
[(in circulating dsDNA)-220.2 (antibody titer after administration of LJP)-238.2 (394.)]TJ
T*
(J Rheumatol 1997;24:314-8.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
1.675 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw 31.325 54.4209 Td
[(7.)-875.1 (Petri M, Hellmann D, Hochber)17.7 (g M. )17.7 (V)110.8 (alidity and reliability of lupus)]TJ
1.675 -1.25 Td
(activity measures in the routine clinic setting. J Rheumatol)Tj
0 Tc 0 Tw T*
(1992;19:53-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Stewart )54.8 (AL, Hays RD, )17.7 (W)79.9 (are JE. )17.7 (The MOS Short-Form general)]TJ
1.675 -1.25 Td
(health survey; reliability and validity in a patient population. Med)Tj
T*
(Care 1988;26:724-35.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Hahn BH. )54.8 (Antibodies to DNA. New Engl J Med 1998;338:1359-68.)]TJ
-0.5 -1.25 Td
[(10.)-875.1 (W)39.8 (infield JB, Faiferman I, Kof)17.7 (fler D. )54.8 (A)74 (vidity of anti-DNA)]TJ
2.175 -1.25 Td
(antibodies in serum and IgG glomerular eluates from patients with)Tj
T*
(systemic lupus glomerulonephritis: association of high avidity)Tj
T*
[(antinative DNA)-220.2 (antibody with glomerulonephritis. J Clin Invest)]TJ
0 Tc 0 Tw T*
(1977;59:90-6.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Rothfield NF)79.7 (, Stollar BD. )17.7 (The relation of immunoglobulin class,)]TJ
2.1381 -1.25 Td
[(pattern of anti-nuclear antibody)64.8 (, and complement-fixing antibodies)]TJ
T*
[(to DNA)-220.2 (in sera from patients with systemic lupus erythematosus. )]TJ
T*
(J Clin Invest 1967;46:1785-94.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Brinkman K, )17.7 (T)69.9 (ermaat R, Berden JH, Smeenk RJ. )54.8 (Anti-DNA)]TJ
2.175 -1.25 Td
[(antibodies and lupus nephritis; the complexity of crossreactivity)64.8 (.)]TJ
0.00729 Tw T*
[(Immunol T)69.9 (oday )-17.8 (1990;1)36.8 (1:232-4.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA)-220.2 (alleles)]TJ
2.175 -1.25 Td
[(are heritable risk factors for lupus nephritis in )54.8 (African )54.8 (Americans. )]TJ
T*
(J Clin Invest 1996;97:1348-54.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Suzuki N, Harada )17.7 (T)74 (, Mizushima )36.8 (Y)128.9 (, Sakane )17.7 (T)74 (. Possible pathogenic)]TJ
2.175 -1.25 Td
[(role of cationic anti-DNA)-220.2 (autoantibodies in the development of)]TJ
T*
(nephritis in patients with systemic lupus erythematosus. J Immunol)Tj
0 Tc 0 Tw T*
[(1993;151:1)36.9 (128-36.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Schneider M, Berning )17.7 (T)74 (,)-0.1 ( )17.7 (W)79.9 (aldendorf M, Glaser J, Gerlach U.)]TJ
2.175 -1.25 Td
(Immunoadsorbent plasma perfusion in patients with systemic lupus)Tj
T*
(erythematosus. J Rheumatol 1990;17:900-7.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Funauchi M, Ikoma S, Enomoto H, et al. High-af)17.7 (finity anti-DNA)]TJ
2.175 -1.25 Td
(antibody parallels clinical course of immunoadsorption therapy for)Tj
T*
(systemic lupus erythematosus. Intern Med 1996;35:367-72.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Silvestris F)79.7 (, D\325Amore O, Caf)17.7 (forio P)110.7 (, Savino L, Dammacco F)79.7 (.)]TJ
2.175 -1.25 Td
(Intravenous immune globulin therapy of lupus nephritis: use of)Tj
T*
(pathogenic anti-DNA-reactive IgG. Clin Exp Immunol)Tj
0 Tc 0 Tw T*
(1996;104:91-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Lee ML, Spertini F)79.7 (, Leimgruber )54.8 (A. Updated phase I clinical results)]TJ
2.175 -1.25 Td
(with an idiotypic vaccine \(3E10\) for systemic lupus erythematosus)Tj
T*
[([abstract]. )54.8 (Arthritis Rheum 1995;8 Suppl:S303. )]TJ
-2.175 -1.25 Td
[(19. )-600.1 (Davis JC, Manzi S, )36.8 (Y)99.8 (arboro C, et al. Recombinant human DNase I)]TJ
2.175 -1.25 Td
(\(rhDNase\) in patients with lupus nephritis. Lupus 1999;8:68-76.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Furie, et al: LJP)-257.3 (394 in SLE)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(265)Tj
ET
0 0 0 0 k
/GS0 gs
102.25 59.08 407.5 -10.83 re
f*
0.5 w
102.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
64 0 obj
<>stream
8;Z\6>E/e/%-.='b]QtRi^Xbt+mmTJ6rg.[TcnS!1D)Q`r2XKop`nU&76H#_0(F>/
ms2']oJQSScg12O;ccUV^ppPJ@h&KTKK$`WbVq*P4A\K04Ab"P(tpl$%_;9]>JeR2
BtHpj*[5.NlmQmmeJ71_qnL%PWK/6DLmF,D:B&nO4qP,]>1/X&/P1]YujP
pid4M2-MJ-NJcp/6TXe6/uZILl]3N#NKccq],Kk?akp-;nm4@jTnf[_[<$O%cF#]_[b!_1fgM:V*NfW[I?@dkV)\l9
V/_.'q[Ma+;MF3fl7;L:.hp[;ns5d2HmDg>R9;I-*9tt6"Vd?F0_bi^/d_@=!^or:
C/O1ocYMUhVi6:r!.^rEjG'\pI\j`F(7>pOe1d'&R,)&'M5bT#'d9tY>=,kJ.R/<^
:G[@O8sWdCLmV3jgBd0fE7/?^jY$Q`ZN95e],
.e,:pk$\[j~>
endstream
endobj
68 0 obj
[/Indexed/DeviceRGB 255 67 0 R]
endobj
67 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
94 0 obj
<>
endobj
40 0 obj
<>
endobj
87 0 obj
<>
endobj
123 0 obj
<>
endobj
147 0 obj
<>
endobj
88 0 obj
<>
endobj
115 0 obj
<>stream
HU{PSg
"/!誈N}hQ-EA @#!! b T[koD]QYS[fnggΙ͙swf߇cfm
YK
Vƥoa\1
g1}&:l5qڜvDQ-H6_,۶nnvT]۩3>>}|E$!g١8]:~sSZ(GR%IyRQAqN|ZX+IITiBue ;:@Eݐbsf~2t:!KgeEzoy NpFGĬ3W]a~͕oǻ=hO9;z7_I.%]6#HhlD;/KT^g(v蝃w"*Zьp|JZzB#O)Q*
<gNFO:*SZNUZvC#^N'xbV8R!tEX?{k7?!2^jĕ2UMaN+A9{}$Ƃ-za ots`[_iKTy6G| E\ PP+((㟊JxsD<urTR,,N)K4W?kuJ,b6PF }U&K*ܭVeڷZNq#=1OE\@s|j'Y@1$
Qn3-aN0y`4e}=MxZ,c$](O*Ҵڼڼ^IV 8RV hQuPONb@،n0@]z]W̕_/OOUILtcNTX(^Nyoބ,EȊ Mii/q8HST;g3d2\dh^ܒ;E=ƓuO*N9ebud3T
W#oX~h
2DxHFEyBI]UXrMY_CIRPr`oSȬ, #9 2g$=BeLg1.Ɏ*k
%iT8iqVO0vF?z/D&ZD